Comment je traite ... un lentigo malin par l'imiquimod topique (Aldara).

Administration, Topical; Aminoquinolines/therapeutic use; Antineoplastic Agents/therapeutic use; Female; Humans; Hutchinson's Melanotic Freckle/drug therapy; Middle Aged; Skin Neoplasms/drug therapy

Abstract :

[en] Lentigo maligna is a special form of in situ cutaneous melanoma that develops on the face of sun worshipers. The topic immunostimulator imiquimod can destroy the neoplasm before it expresses its invasive potential. A strict clinical follow-up of the treated zone must be observed at least 5 years to detect any early sign of recurrence.

Disciplines :

Dermatology

Author, co-author :

Bourguignon, Raphaël; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Paquet, Philippe ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Quatresooz, Pascale ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Pierard, Gérald ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Language :

French

Title :

Comment je traite ... un lentigo malin par l'imiquimod topique (Aldara).

Alternative titles :

[en] How I treat ... lentigo maligna by topical imiquimod.

Publication date :

2005

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

691-4

Peer reviewed :

Peer reviewed

Available on ORBi :

since 20 February 2009

Statistics

Number of views

202 (3 by ULiège)

Number of downloads

447 (9 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Chapman MS, Spencer SK, Brennick JB.-Histologic resolution of melanoma in situ (lentigo maligna) with 5% imiquimod cream. Arch Dermatol, 2003, 139, 943-944.
Ahmed I, Berth-Jones J.-Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol, 2000, 143, 843-845.
Henry C, Lapière M, Franchimont C, et al.-Immunotherapy by dinitrochlorobenzene of melanomas of the skin. I- Methods, clinical effects and survivial rates. In: Pathology of malignant melanoma. Ed. A.B. Ackerman, Publ. Masson, New York, 1981, 367-371.
Piérard GE, Henry C, Franchimont C, et al.-Immunotherapy by dinitrochlorobenzene of melanomas of the skin. II- Histology of the cytotoxic effect. In: Pathology of malignant melanoma. Ed. A.B. Ackerman, Publ. Masson, New York, 1981, 373-385.
Ormond P, Blasdale C, Leondard N, et al.-Treatment of lentigo maligna with imiquimod. Br J Dermatol, 2002, 147, S57-S59.
Naylor MF, Crowson N, Kuwahara R, et al.-Treatment of lentigo maligna with topical imiquimod. Br J Dermatol, 2003, 149, 66-69.
Powell AM, Russell-Jones R, Barlow J.-Topical imiquimod immunotherapy in the management of lentigo maligna. Clin Dermatol, 2004, 29, 15-21.
Urosevic M, Dummer R.-Role of imiquimod in skin cancer treatment. Am J Clin Dermatol, 2004, 5, 453-458.
Piérard-Franchimont C, Arrese JE, Cornil F, et al.-Les mélanomes cutanés, un spectre de cancers émergents chez la femme en région wallonne. Rev Med Liège, 1999, 4, 495-499.
Diepgen TL, Mahler V.-The epidemiology of skin cancer. Br J Dermatol, 2002, 146, S1-S6.
Quatresooz P, Uhoda I, Fumal I, et al.-Revisiting the gender-linked melanoma burden. Dermatology, 2004, 209, 197-201.
Uhoda I, Quatresooz P, Fumal I, et al.-Updating trends in cutaneous cancers in south-east Belgium. Oncol Reports, 2004, 12, 111-114.
Slade HB.-Cytokine induction and modifying the immune response to human papilloma virus with imiquimod. Eur J Dermatol, 1998, 8, S13-S16.
Slade HB, Owens ML, Tomai MA, et al.-Imiquimod 5% cream (Aldara). Exp Opin Invest Drugs, 1998, 7, 437-442.
Hermanns-Lê T, Nikkels AF, Uhoda I, et al.-L'imiquimod (Aldara®): un immunomodulateur pour la peau. Rev Med Liège, 2002, 57, 116-118.
Uhoda I, Quatresooz P, Piérard-Franchimont C, et al.-Nudging epidermal field cancerogenesis by imiquimod. Dermatology, 2003, 206, 357-360.
Piérard-Franchimont C, Arrese JE, Nikkels AF, et al.-Factor XIIIa-positive dermal dendrocytes and proliferative activity of cutaneous cancers. Virchows Arch, 1996, 429, 43-48.
Arrese JE, Paquet P, Claessens N, et al.-Dermal dendritic cells in anogenital warty lesions unresponsive to an immune-response modifier. J Cutan Pathol, 2001, 28, 131-134.
Hermanns-Lê T, Paquet P, Nikkels AF, et al.-Prolonged imiquimod treatment and graft-versus-host reaction: histological mimicry in the pattern of monocyte macrophage-dendrocyte lineage skin infiltration. Dermatology, 2003, 206, 361-365.
Quatresooz P, Piérard GE.-Imiquimod- responsive basal cell carcinomas and factor XIIIa-enriched dendrocytes. Clin Exp Dermatol, 2003, 28, S27-S29.
Michalopoulos P, Yawalkar N, Brönnimann M, et al.-Characterization of the cellular infiltrate during successful topical treatment of lentigo maligna with imiquimod. Br J Dermatol, 2004, 151, 903-906.
Zitelli JA.-Use of imiquimod for treating skin cancer. J Am Acad Dermatol, 2005, 52, 177.
Quatresooz P, Arrese JE, Piérard-Franchimont C, et al.-Immunohistochemical aid at risk stratification of melanocytic neoplasms. Int J Oncol, 2004, 24, 211-216.
Claessens N, Piérard GE, Piérard-Franchimont C, et al.-Immuno-histochemical detection of incipient melanoma micrometastases. Relationship with sentinel lymph node involvement. Melanoma Res, sous presse.
Steinmann A, Funk JO, Schuler G, et al.-Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol, 2000, 43, 555-556.
Bong AB, Bonnekoh B, Franke I, et al.-Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology, 2002, 205, 135-138.
Ugurel S, Wagner A, Pfohler C, et al.-Topical imiquimod eradictes skin metastases of malignant melanoma but fails to prevent rapid lymphogenous metastatic spread. Br J Dermatol, 2002, 147, 621-624.
Vereecken P, Mathieu A, Laporte M, et al.-Management of cutaneous locoregional recurrences of melanoma: a new therapeutic perspective with imiquimod. Dermatology, 2003, 206, 279-280.
Wolf IH, Smolle J, Binder B, et al.-Topical imiquimod in the treatment of metastatic melanoma to skin. Arch Dermatol, 2003, 139, 273-276.
Quatresooz P, Uhoda I, Piérard-Franchimont C, et al.-Héliodermie, héliophiles et héliophobes. Rev Med Liège, 2005, 60, S53-S55.
Petit L, Fogouang L, Uhoda I, et al.-Regional variability in mottled photo-induced melanoderma in the elderly. Exp Gerontol, 2003, 38, 327-331.
Quatresooz P, Petit L, Uhoda I, et al.-Mosaic subclinical melanoderma. An Achilles heel for UV-related epidermal carcinogenesis? Int J Oncol, 2004, 25, 1763-1768.
Uhoda I, Quatresooz P, Rorive A, et al.-Photocancérogenèse cutanée. Rev Med Liège, 2005, 60, S84-S93.
Henry F, Piérard-Franchimont C, Piérard GE.-Photoprotection cutanée. Rev Med Liège, 2005, 60, S98-S103.
Petit L, Piérard GE.-Skin-lightening products revisited. Int J Cosmet Sci, 2003, 25, 169-181.
Paquet P, Piérard GE.-Intense pulsed light treatment of persistent facial hypermelanosis following drug-induced toxic epidermal necrolysis. Dermatol Surg, 2004, 30, 1522-1525.
Paquet P, Piérard-Franchimont C, Henry F, et al.-Traitements par lasers et lumière pulsée. Rev Med Liège, 2005, 60, S113-S119.